Consolidated guidance about materials licenses : program-specific guidance about commercial radiopharmacy licenses, draft report for comment /

Bibliographic Details
Main Author: Elliot, R. L. (Author)
Format: Government Document eBook
Language:English
Published: Washington, DC : United States Nuclear Regulatory Commission, Office of Nuclear Material Safety and Safeguards, December 2016.
Edition:Revised 2.
Subjects:
Online Access:https://purl.fdlp.gov/GPO/gpo76460

MARC

Tag First Indicator Second Indicator Subfields
LEADER 00000cam a2200000Ii 4500
001 in00003710941
005 20211120181729.0
006 m o d f
007 cr |||||||||||
008 170124e201612 dcua ot f000 0 eng d
035 |a (OCoLC)ocn969906160 
040 |a GPO  |b eng  |e rda  |e pn  |c GPO  |d GPO  |d MvI  |d UtOrBLW 
043 |a n-us--- 
049 |a WWW 
074 |a 1051-H-48 (online) 
086 0 |a Y 3.N 88:10/1556/V.13/REV.2/DRAFT 
100 1 |a Elliot, R. L.,  |e author. 
245 1 0 |a Consolidated guidance about materials licenses :  |b program-specific guidance about commercial radiopharmacy licenses, draft report for comment /  |c prepared by R. L Elliot [and five others]. 
246 3 |a Program-specific guidance about commercial radiopharmacy licenses, draft report for comment 
250 |a Revised 2. 
264 1 |a Washington, DC :  |b United States Nuclear Regulatory Commission, Office of Nuclear Material Safety and Safeguards,  |c December 2016. 
300 |a 1 online resource (various pagings) :  |b illustrations 
336 |a text  |b txt  |2 rdacontent 
337 |a computer  |b c  |2 rdamedia 
338 |a online resource  |b cr  |2 rdacarrier 
588 |a Description based on online resource; title from PDF title page (viewed on Jan. 12, 2017). 
500 |a "NUREG-1556, volume 13, Rev. 2." 
500 |a "Manuscript completed: December 2016; date published: December 2016." 
500 |a "Performing organization: Division of Material Safety, State, Tribal, and Rulemaking Programs, Office of Nuclear Material Safety and Safeguards, U.S. Nuclear Regulatory Commission"--Bibliographic data sheet. 
513 |a Technical report;  |b Nov. 2007-Dec. 2016. 
650 0 |a Radiopharmaceuticals  |z United States. 
650 0 |a Radioisotopes in pharmacology  |z United States. 
650 0 |a Nuclear industry  |x Licenses  |z United States. 
710 2 |a U.S. Nuclear Regulatory Commission.  |b Office of Nuclear Material Safety and Safeguards,  |e issuing body.  |0 http://id.loc.gov/authorities/names/n77012267 
776 0 8 |i Print version:  |a Elliot, R. L.  |t Consolidated guidance about materials licenses  |w (OCoLC)969906304 
856 4 0 |u https://purl.fdlp.gov/GPO/gpo76460  |t 0 
999 f f |s 046bcdcf-d733-3083-833e-446c06e44c59  |i 656f4f5b-dea9-368c-a3a0-78778c0d7af9  |t 0 
952 f f |a Texas A&M University  |b College Station  |c Electronic Resources  |d Available Online  |t 0  |e Y 3.N 88:10/1556/V.13/REV.2/DRAFT  |h Superintendent of Documents classification 
998 f f |a Y 3.N 88:10/1556/V.13/REV.2/DRAFT  |t 0  |l Available Online